PubRank

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Clinical Trial ID NCT01625234

PubWeight™ 20.84‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01625234

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014 2.26
2 Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011 2.06
3 Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015 1.61
4 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 1.48
5 Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015 1.24
6 Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014 1.19
7 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
8 Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014 1.05
9 A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014 0.93
10 Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers (Basel) 2015 0.90
11 Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med 2015 0.88
12 ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016 0.86
13 Targeting genomic alterations in squamous cell lung cancer. Front Oncol 2013 0.85
14 Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2013 0.81
15 Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016 0.79
16 New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. Oncotarget 2015 0.78
17 The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Dis Model Mech 2016 0.77
18 Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol 2015 0.76
19 Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016 0.75
20 Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. J Thorac Dis 2016 0.75
21 Targeted therapy in cancer. Cancer Chemother Pharmacol 2015 0.75
22 Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book 2015 0.75
Next 100